| PubMed |
Abstract |
RScore(About this table) |
| 19084294 |
Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, De Cesare M, Zunino F: Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. Epub 2008 Nov 19.
|
32(0,1,1,2) |
Details |
| 17851643 |
Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, Kim DK, Bang YJ, Kim TY: Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med. 2008 Jan;86(1):117-28. Epub 2007 Sep 13.
|
3(0,0,0,3) |
Details |
| 19060243 |
Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW: Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood. 2009 Feb 26;113(9):1982-91. Epub 2008 Dec 5.
|
2(0,0,0,2) |
Details |
| 19074726 |
Chen J, Fiskus W, Eaton K, Fernandez P, Wang Y, Rao R, Lee P, Joshi R, Yang Y, Kolhe R, Balusu R, Chappa P, Natarajan K, Jillella A, Atadja P, Bhalla KN: Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood. 2009 Apr 23;113(17):4038-48. Epub 2008 Dec 12.
Pan-histone deacetylase inhibitors, for example, vorinostat and panobinostat (LBH589; Novartis Pharmaceuticals, East Hanover, NJ), have shown clinical efficacy against advanced cutaneous T-cell lymphoma (CTCL). |
2(0,0,0,2) |
Details |
| 17762392 |
Kim BS, Bae E, Kim YJ, Ahn KS, Park J, Rhee JY, Lee YY, Kim Y, Lee D, Kim BK, Yoon SS: Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs. 2007 Jul;18(6):641-7.
|
2(0,0,0,2) |
Details |
| 19805519 |
Chen S, Dai Y, Pei XY, Grant S: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol. 2009 Dec;29(23):6149-69. Epub 2009 Oct 5.
|
1(0,0,0,1) |
Details |
| 19553350 |
Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB: Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol. 2009 Sep;297(3):F729-39. Epub 2009 Jun 24.
Histone deacetylase (HDAC) determines the acetylation status of histones and thereby controls the regulation of gene expression. |
1(0,0,0,1) |
Details |